11:00am-12:30pm

Hematopathology virtual webinar
Sanam Loghavi, Mina Xu, Robert Hasserjian

• Diagnostic assessment and differential diagnosis of fibrotic and hypoplastic bone marrow specimens
  Robert Hasserjian
  

Panel discussion

• The phenotypic spectrum of TP53 mutations in myeloid neoplasms
  Sanam Loghavi

Panel discussion

• Tackling clonal hematopoiesis and germline predispositions to myeloid neoplasms
  Mina Xu

Panel Discussion

• Diagnostic assessment, clinical consequences and differential diagnostic considerations of hypoplastic bone marrow
  Anne Sophie Kubasch

Panel Discussion

1:00pm-2:30pm

Meeting Registration

2:30pm-2:40pm

Introduction & meeting objectives and keynote talks – Amer Zeidan

2:40pm-3:20pm

Session I: CHIP/CCUS – Michael Savona and Uma Borate     

• The SEARCH CONSORTIUM: Looking for Answers in CHIP And CCUS; Zhuoer Xie
• Clonal Hematopiesis and transplantation outcomes; Coleman Lindsley
• Should CCUS be considered as lower risk MDS?; Uma Borate
• Putting it all together; Michael Savona

Panel discussion

3:50pm-4:10pm

Break

 

4:10pm-4:30pm

Keynote talk:

Leveraging the icMDS combined database to answer timely and important questions

on classification and risk stratification in MDS: Matteo Della Porta

4:30pm-5:0pm

Session II: CMML – Michael Savona and Valeria Santini                   

• RASopathies; Key Features of Ras-Family Mutated CMML, and Treatment Options; Mrinal Patnaik
• Approaches from the MDS/MPN IWG: ABNL MARRO, and beyond; Daniel Wiseman
• Elucidating the role of HMAs in CMML-A standard of care or not? Lisa Pleyer
• The Special Case of MDS/MPN-RS-T; Valeria Santini

Panel discussion

5:20pm-5:45pm

Lifetime Awards

 5:45pm-5:50pm

Wrap-up Day 1

8:00am-9:10am

Session III: Epigenetics and Splicing

Chairs: Valeria Santini and Elizabeth Griffiths                                    

• Oral hypomethylating agents in MDS-what is next?; Elizabeth Griffiths
• Updates in therapeutic combinations of epigenetic agents in MDS/AML; Aristoteles Giagounidis
• Pathophysiology and targeting of splicing factor mutant MDS and CMML; Jacqueline Boultwood
• Overview of the NIH Program for MDS; Alain Mina

Panel discussion

9:20am-10:20am

Session IV: Inflammation and Immune interventions

Chairs: Andrew Wei and Rena Buckstein                                                                                                

• Targeting inflammation & dysregulated innate immunity in MDS; Shahram Kordasti
• Updates in Vexas Syndrome; Carmelo Gurnari
• IRAK inhibitors in MDS and AML; Uwe Platzbecker
• How can we optimize transplant outcomes for MDS?; Charles Craddock
• What we have learn from AML immune contexture that can be relevant to MDS?; Leonido Luznik

Panel discussion

 

10:40am-1:10pm

Session V: Classification and risk stratification Updates

Chairs: Rena Buckstein and Maria Teresa Voso

• Roadmap for harmonization of classifications; Somedeb Ball
• Molecular data integration in prognostic tools; Elli Papaemmanuil
• Prognosis assessment in resource-limited countries; Maria Teresa Voso
• Predicting relapse risk in MDS post-transplant: Ready for primetime? Christopher Hourigan
• The Role of Classification versus Prognostication in MDS Patients; Robert Hasserjian

Panel discussion

2:10pm-3:00pm

Session VI: Response assessment & regulatory considerations

Chairs:  Amer Zeidan/Kelly Norsworthy     

• Proceedings from FDA/NCI workshop on drug development in MDS; Kelly Norsworthy
• How can we measure disease modification in LR-MDS; Rami Komrokji
• Are molecular responses ready for prime time use in MDS? Katharina Götze
• IWG response criteria evolution for higher risk MDS; Amer Zeidan

Panel discussion

3:00pm-3:20pm

Break

3:30pm-4:20pm

Session VII: TP53 aberrations and Secondary AML

Chairs: Valeria Santini & Andrew Wei 

• How to use TP53 status for clinical decisions in MDS?; Coleman Lindsley
• Therapies for secondary AML; Thomas Cluzeau
• Targeting the CD47-SIRPa axis in MDS/AML; David Sallman
• TP53 focused initiative in MDS MyeloMatch; Maximilian Stahl
• Putting it together: current and future perspectives in TP53 mutated AML; Andrew Wei

Panel discussion

4:20pm-5:40pm

Session VIII: Advances in LR-MDS therapies

Chairs: Uwe Platzbecker & Olatoyosi Odenike   

• Telomerase inhibition; Uwe Platzbecker
• TGF pathway modulation; Lionel Ades
• Should lenalidomide become SOC in del5q LR-MDS before needing transfusions? María-Díez Campelo
• myeloMATCH efforts to move clinical trial development ahead in MDS; Olatoyosi Odenike
• Putting it together-how do I manage LR-MDS in 2023; Valeria Santini

Panel discussion

9:00am-10:10am

Session IX: Updates in HR-MDS therapies

Chairs: Andrew Wei and Amer Zeidan

• IDH inhibitors- mono or combination therapy in MDS?;  Marie Sebert
• RARA agonists- Updates in use of RARA agonists in MDS?; Amy DeZern
• Updates on TIM3 targeting in MDS and AML?; Amer Zeidan
• Putting all together; New directions in management of HR-MDS Andrew Wei

 

Panel discussion

10:00am-11:20am

Session X: Big data and quality of life measures 

Chairs: Rena Buckstein and Mikkael Sekeres

• Should we include frailty and geriatric assessment in prognostic tools; Rena Buckstein
• The HARMONY Alliance: A Big Data platform for patients with hematologic malignancies; Guillermo Sanz
• Artificial Intelligence for MDS prognostication; Adrián Mosquera Orgueira
• QOL in MDS: what are its predictors and what does it predict?; Fabio Efficace
• How should we integrate quality of life as an endpoint in trials; Mikkael Sekeres

Panel discussion

11:20am-11:40am

break                          

11:40am-12:25pm                                                        

Open forum discussion and future plans for iwMDS       

12:25pm-12:30pm                               

Conclusions and closing remarks-Amer Zeidan